Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of bimagrumab and tirzepatide in obesity/overweight with type 2 diabetes
jRCT2031250007Phase 2Suspended
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of bimagrumab and tirzepatide in obesity, Overweight and type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight. Started May 2025; status: suspended.
02
Drugs
bimagrumabtirzepatide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031250007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250007.